Hydroalcoholic extract ofCarum carviL. in oral mucositis: a clinical trial in male golden hamsters

Oral Diseases ◽  
2015 ◽  
Vol 22 (1) ◽  
pp. 39-45 ◽  
Author(s):  
M Mardani ◽  
SM Afra ◽  
N Tanideh ◽  
A Andisheh Tadbir ◽  
F Modarresi ◽  
...  
2020 ◽  
Vol 31 (3) ◽  
pp. 310-318
Author(s):  
Nader Tanideh ◽  
Arash Badie ◽  
Raha Habibagahi ◽  
Omid koohi-Hosseinabadi ◽  
Sara Haghnegahdar ◽  
...  

Abstract Oral mucositis is a common inflammatory complication among patients with cancer. This study evaluated the histopathological, stereological, and antioxidant markers of 2% eucalyptus extract in induced oral mucositis in male golden hamsters. In this animal study, oral mucositis was induced in 30 male golden hamsters by 5-FU (60 mg/kg) on days 0, 5, and 10 of the study. The cheek pouch was scratched with a sterile needle once daily on days 3 and 4. On days 14-17, 2% eucalyptus hydroalcoholic extract gel and Calendula officinalis extract gel groups were treated and then compared with a non-treated control group. The histopathological and stereological scores and the pouch content of malondialdehyde, as well as the activities of glutathione and myeloperoxidase in the pouch tissue, were evaluated. Histopathologic scores of oral mucositis were lower in the eucalyptus gel group than those of the calendula and control groups (p<0.05). Also, a lower malondialdehyde level and higher myeloperoxidase and glutathione activities were detected in the eucalyptus group in comparison to the calendula and control groups (p<0.001). The thickness of the mucosa and submucosa increased in the eucalyptus group. The numerical density of the fibroblast and the volume density of the collagen significantly increased in the eucalyptus group. In conclusion, the use of eucalyptus hydroalcoholic extract may be associated with reduced intensity of oral mucositis, diminished concentration of malondialdehyde, increased activity of myeloperoxidase and glutathione, increased volume of mucosa and submucosa, increased fibroblast and collagen in the induced oral mucositis in golden hamsters undergoing 5-FU consumption.


Author(s):  
Mariana Bitu Ramos-Pinto ◽  
Teresa Paula de Lima Gusmão ◽  
Jayr Schmidt-Filho ◽  
Graziella Chagas Jaguar ◽  
Manoela Domingues Martins ◽  
...  

BMJ Open ◽  
2018 ◽  
Vol 8 (10) ◽  
pp. e019505
Author(s):  
Núbia de Cassia Almeida Queiroz ◽  
Michelle Pedroza Jorge ◽  
Ilza Maria de Oliveira Sousa ◽  
Carmen Silvia Passos Lima ◽  
Maria Christina de Miranda Matias ◽  
...  

IntroductionOral mucositis is an iatrogenic condition of erythematous inflammatory changes which tends to occur on buccal and labial surfaces, the ventral surface of the tongue, the floor of the mouth and the soft palate of patients receiving chemotherapy. This protocol of ongoing randomised parallel group clinical trial aims to access the therapeutic effect of an herbal gel containing 2.5%Arrabidaea chicaVerlot standardised extract on oral mucositis in patients with head and neck cancer compared with low-level laser therapy.Methods and analysisPatients with head and neck cancer held at Clinics Hospital of University of Campinas, Sao Paulo, who develop early signs/symptoms of oral mucositis are eligible. Baseline characteristics of participants include oral mucositis grade and quality of life assessments. Enrolment started in November 2017 with allocation of patients to one of the study groups by means of randomisation. Patients will be treated either withArrabidaea chicaor laser until wound healing. Monitoring includes daily assessment of mucositis grade and diameter measurement by photographs and millimetre periodontal probe. Treatments will be concluded once mucositis is healed. A blinded assessor will evaluate mucositis cure after referred by the study team. At this point, the gel tube will be weighed to indirectly assess patient’s compliance. At close-out, data will be analysed by a blinded researcher following the procedures described in the statistical analyses.Ethics and disseminationThis clinical trial was approved by the ethics committee of research in humans at the Faculty of Medical Sciences of University of Campinas (report no. 1,613,563/2016). Results from this trial will be communicated in peer-reviewed publications and scientific presentations.Trial registration numberRBR-5×4397.


Sign in / Sign up

Export Citation Format

Share Document